Kaiyuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kaiyuan Liu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Dong Yang
Department of Orthopaedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
2 shared publicationsGuo-Dong Li
Department of Orthopaedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
2 shared publicationsHai-Yang Yu
Department of Orthopaedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
2 shared publicationsJi-Yang Lv
State Key Laboratory of Microbial Metabolism, Sheng Yushou Center of Cell Biology and Immunology, School of Life Science and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, P.R. China
2 shared publicationsLin Fan
Department of Orthopaedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
2 shared publicationsQiu-Ming Gao
Department of Orthopaedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
2 shared publications
Latest Publications
- Open Access
- 15 January 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Therapeutic implications and comprehensive insights into cellular senescence and aging in the tumor microenvironment of sarcoma
Sarcoma (SARC), a diverse group of stromal tumors arising from mesenchymal tissues, is often associated with a poor prognosis. Emerging evidence indicates that senescent cells within the tumor microenvironment (TME) significantly contribute to cancer progression and metastasis. Although the influence of senescence on SARC has been partially acknowledged, it has yet to be fully elucidated. In this study, we revealed that senescence level and age were associated with TME, immune treatment indicators, and prognosis in SARC. Utilizing the weighted gene co-expression network analysis and least absolute shrinkage and selection operator algorithm, we identified senescence-related genes and developed a senescence predictor. Three genes, RAD54, PIK3IP1, and TRIP13, were selected to construct a multiple linear regression model. Validation cohorts, immunohistochemistry, and quantitative reverse transcription polymerase chain reaction confirmed that the predictor derived from these three genes possessed prognostic and pathological relevance. Our senescence predictor provides comprehensive insights into the molecular mechanisms of SARC and identifies potential biomarkers for prognosis, paving the way for effective treatments. The results of this study hold promise for developing therapeutic strategies tailored to the unique characteristics of SARC.
- 15 January 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Open AccessTherapeutic implications and comprehensive insights into cellular senescence and aging in the tumor microenvironment of sarcoma
Sarcoma (SARC), a diverse group of stromal tumors arising from mesenchymal tissues, is often associated with a poor prognosis. Emerging evidence indicates that senescent cells within the tumor microenvironment (TME) significantly contribute to cancer progression and metastasis. Although the influence of senescence on SARC has been partially acknowledged, it has yet to be fully elucidated. In this study, we revealed that senescence level and age were associated with TME, immune treatment indicators, and prognosis in SARC. Utilizing the weighted gene co-expression network analysis and least absolute shrinkage and selection operator algorithm, we identified senescence-related genes and developed a senescence predictor. Three genes, RAD54, PIK3IP1, and TRIP13, were selected to construct a multiple linear regression model. Validation cohorts, immunohistochemistry, and quantitative reverse transcription polymerase chain reaction confirmed that the predictor derived from these three genes possessed prognostic and pathological relevance. Our senescence predictor provides comprehensive insights into the molecular mechanisms of SARC and identifies potential biomarkers for prognosis, paving the way for effective treatments. The results of this study hold promise for developing therapeutic strategies tailored to the unique characteristics of SARC.
- Open Access
- 31 May 2021
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 59 (1) , 1-11
CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition
Doxorubicin is one of the most frequently used chemotherapy drugs in the treatment of osteosarcoma (OS), but the emergence of chemoresistance often leads to treatment failure. C‑X‑C motif chemokine receptor 4 (CXCR4) has been demonstrated to regulate OS progression and metastasis. However, whether CXCR4 is also involved in OS chemoresistance and its molecular mechanisms has yet to be fully elucidated. In the present study, CXCR4‑mediated autophagy for OS chemotherapy was investigated by western blot analysis, transmission electron microscopy and confocal microscopy. CXCR4 silencing enhanced doxorubicin‑induced apoptosis by reducing P‑glycoprotein in CXCR4+ LM8 cells, while CXCR4 overexpression promoted OS doxorubicin resistance in CXCR4‑ Dunn cells. Furthermore, CXCR4 silencing with or without doxorubicin increased the expression of beclin 1 and light chain 3B, and the number of autophagosomes and autolysosomes, as well as induced autophagic flux activation by suppressing the PI3K/AKT/mTOR signaling pathway. In addition, pretreatment with the autophagy inhibitor bafilomycin A1 attenuated CXCR4 abrogation‑induced cell death. Finally, the CXCR4 antagonist AMD3100 synergistically reinforced the antitumor effect of doxorubicin in an orthotopic OS mouse model. Taken together, the present study revealed that CXCR4 inhibition sensitizes OS to doxorubicin by inducing autophagic cell death. Therefore, targeting the CXCR4/autophagy axis may be a promising therapeutic strategy to overcome OS chemotherapy resistance.
- 31 May 2021
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 59 (1) , 1-11
Open AccessCXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition
Doxorubicin is one of the most frequently used chemotherapy drugs in the treatment of osteosarcoma (OS), but the emergence of chemoresistance often leads to treatment failure. C‑X‑C motif chemokine receptor 4 (CXCR4) has been demonstrated to regulate OS progression and metastasis. However, whether CXCR4 is also involved in OS chemoresistance and its molecular mechanisms has yet to be fully elucidated. In the present study, CXCR4‑mediated autophagy for OS chemotherapy was investigated by western blot analysis, transmission electron microscopy and confocal microscopy. CXCR4 silencing enhanced doxorubicin‑induced apoptosis by reducing P‑glycoprotein in CXCR4+ LM8 cells, while CXCR4 overexpression promoted OS doxorubicin resistance in CXCR4‑ Dunn cells. Furthermore, CXCR4 silencing with or without doxorubicin increased the expression of beclin 1 and light chain 3B, and the number of autophagosomes and autolysosomes, as well as induced autophagic flux activation by suppressing the PI3K/AKT/mTOR signaling pathway. In addition, pretreatment with the autophagy inhibitor bafilomycin A1 attenuated CXCR4 abrogation‑induced cell death. Finally, the CXCR4 antagonist AMD3100 synergistically reinforced the antitumor effect of doxorubicin in an orthotopic OS mouse model. Taken together, the present study revealed that CXCR4 inhibition sensitizes OS to doxorubicin by inducing autophagic cell death. Therefore, targeting the CXCR4/autophagy axis may be a promising therapeutic strategy to overcome OS chemotherapy resistance.
- Open Access
- 2 December 2020
- Published by Springer Nature in Research Square
CXCR4 Blockade Enhances The Sensitivity Of Osteosarcoma To Doxorubicin By Inducing Autophagic Cell Death Via PI3K-Akt-Mtor Pathway Inhibition
Background: Doxorubicin is one of the most frequent used chemotherapy drugs in the treatment of osteosarcoma (OS), but the emergence of chemoresistance often leads to its treatment failure. CXCR4 has been proved to regulate osteosarcoma progression and metastasis, however whether CXCR4 is also implicated in OS chemoresistance and its molecular mechanisms have not yet been fully elucidated. In this study, we investigated CXCR4-mediated autophagy for OS chemotherapy. Methods: Cell viability, western blot and apoptosis were performed to evaluate doxorubicin resistance after CXCR4 regulation (downregulation or upregulation) and treatment with autophagy modulators (bafilomycin A1 or rapamycin) in two OS cell lines (LM8 and Dunn). Autophagy-related proteins (Beclin1 and LC3B) detected by western blot, autophagosomes and autolysosomes observed by transmission electron microscopy, and autophagic flux monitored by confocal microscopy were utilized to comprehensively assess autophagy level changes. A C3H mouse osteosarcoma orthotopic model was established to determine anti-tumor effect of CXCR4 antagonist AMD3100 and doxorubicin in vivo.Results: CXCR4 inhibition enhanced doxorubicin-induced apoptosis by reducing p-glycoprotein, while CXCR4 overexpression promoted OS doxorubicin resistance. Moreover, CXCR4 inhibition combined with or without doxorubicin increased Beclin1 and LC3B expression, numbers of autophagosome and autolysosome, and induced autophagic flux activation by suppressing PI3K-Akt-mTOR pathway. In addition, pretreatment with autophagy inhibitor bafilomycin A1 attenuated CXCR4 abrogation-induced cell death. Finally, CXCR4 antagonist AMD3100 synergistically reinforced anti-tumor effect of doxorubicin in orthotopic OS mouse model. Conclusions: This study revealed CXCR4 inhibition sensitizes OS to doxorubicin by inducing autophagic cell death. Targeting CXCR4/autophagy axis may be a promising therapeutic strategy to overcome OS chemotherapy resistance.
- 2 December 2020
- Published by Springer Nature in Research Square
Open AccessCXCR4 Blockade Enhances The Sensitivity Of Osteosarcoma To Doxorubicin By Inducing Autophagic Cell Death Via PI3K-Akt-Mtor Pathway Inhibition
Background: Doxorubicin is one of the most frequent used chemotherapy drugs in the treatment of osteosarcoma (OS), but the emergence of chemoresistance often leads to its treatment failure. CXCR4 has been proved to regulate osteosarcoma progression and metastasis, however whether CXCR4 is also implicated in OS chemoresistance and its molecular mechanisms have not yet been fully elucidated. In this study, we investigated CXCR4-mediated autophagy for OS chemotherapy. Methods: Cell viability, western blot and apoptosis were performed to evaluate doxorubicin resistance after CXCR4 regulation (downregulation or upregulation) and treatment with autophagy modulators (bafilomycin A1 or rapamycin) in two OS cell lines (LM8 and Dunn). Autophagy-related proteins (Beclin1 and LC3B) detected by western blot, autophagosomes and autolysosomes observed by transmission electron microscopy, and autophagic flux monitored by confocal microscopy were utilized to comprehensively assess autophagy level changes. A C3H mouse osteosarcoma orthotopic model was established to determine anti-tumor effect of CXCR4 antagonist AMD3100 and doxorubicin in vivo.Results: CXCR4 inhibition enhanced doxorubicin-induced apoptosis by reducing p-glycoprotein, while CXCR4 overexpression promoted OS doxorubicin resistance. Moreover, CXCR4 inhibition combined with or without doxorubicin increased Beclin1 and LC3B expression, numbers of autophagosome and autolysosome, and induced autophagic flux activation by suppressing PI3K-Akt-mTOR pathway. In addition, pretreatment with autophagy inhibitor bafilomycin A1 attenuated CXCR4 abrogation-induced cell death. Finally, CXCR4 antagonist AMD3100 synergistically reinforced anti-tumor effect of doxorubicin in orthotopic OS mouse model. Conclusions: This study revealed CXCR4 inhibition sensitizes OS to doxorubicin by inducing autophagic cell death. Targeting CXCR4/autophagy axis may be a promising therapeutic strategy to overcome OS chemotherapy resistance.